XBiotech (XBIT) Gross Margin (2020 - 2022)

XBiotech (XBIT) posted quarterly Gross Margin of 94.67% for Q4 2022, up 8.56% quarter-over-quarter from 87.2% in Q3 2022.

XBiotech (XBIT) Gross Margin (2020 - 2022) Analysis & Trends

XBiotech's Gross Margin history runs 3 years deep, the most recent figure standing at 94.67% for Q4 2022.

In Q4 2022, Gross Margin changed N/A year-over-year to 94.67%; the TTM figure through Sep 2023 stood at 94.67% (up 1533.0% YoY), while the FY2022 annual figure was 83.77%, up 1541.0% from the prior year.
Gross Margin for Q4 2022 stood at 94.67%, up from 87.2% in the prior quarter.
The five-year high for Gross Margin was 94.67% in Q4 2022, with the low at 8.83% in Q4 2020.
The 3-year median for Gross Margin is 57.4% (2022), against an average of 51.27%.
The sharpest annual moves came in 2021 and 2022: Gross Margin jumped 6479 bps in 2021, then jumped 491 bps in 2022.
XBiotech's Gross Margin stood at 8.83% in 2020, then surged by 955 bps to 75.44% in 2021, then increased by 25 bps to 94.67% in 2022.
Business Quant data shows XBIT's Gross Margin at 94.67% in Q4 2022, 87.2% in Q3 2022, and 86.47% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	XBiotech	68.90 Mn	68.90 Mn	-	-

Download Data